A type of anticancer drug, the farnesyltransferase inhibitors (FTIs), has been proposed, but their use has been mostly limited to animal models.[32] A Phase II clinical trial using the FTI lonafarnib began in May 2007.[33] In studies on the cells another anti-cancer drug, rapamycin, caused removal of progerin from the nuclear membrane through autophagy.[18][34] It has been proved that pravastatin and zoledronate are effective drugs when it comes to the blocking of farnesyl group production.